Key result
CCR registry evaluates real-world adoption and clinical outcomes of prasugrel in PCI-treated ACS patients.
Why the study?
There is limited experience with the use of prasugrel in routine clinical practice for PCI-treated ACS patients despite guideline recommendations.
What are the real-world benefits and risks of prasugrel as first-choice antiplatelet therapy in PCI-treated ACS patients?
Observational (n=4,000)
Yes
What are the real-world benefits and risks of prasugrel as first-choice antiplatelet therapy in PCI-treated ACS patients?
The CCR registry is designed to evaluate the real-world adoption, benefits, and risks of prasugrel in PCI-treated ACS patients.
Answers are grounded in this paper and cite their sources.
Observational registry may inform prasugrel adoption in ACS; leaves open real-world benefits and risks without randomized confirmation.
BACKGROUND: Platelet inhibition is crucial in reducing both short- and long-term atherothrombotic risks in patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI). Based on randomised trials, recent recommendations in the current guidelines include the endorsement of prasugrel as a first-choice adenosine diphosphate receptor inhibitor. Yet, there is limited experience with the use of prasugrel in routine practice. METHODS: The Rijnmond Collective Cardiology Research (CCR) registry is a prospective, observational study that will follow-up 4000 PCI-treated ACS patients in the larger region of Rotterdam, the Netherlands. Based on recently implemented hospital protocols, all patients will receive prasugrel as first-choice antiplatelet agent, unless contraindicated, in accordance with European guidelines, and will be followed for up to 1 year post-discharge for longitudinal assessment of outcomes and bleeding events. This registry exemplifies a collaborative study design that employs a regional PCI registry platform and provides feedback to participating sites regarding their practice patterns, thereby supporting and promoting improvement of quality of care. CONCLUSION: The CCR registry will evaluate the adoption of prasugrel into routine clinical practice and thus, will provide important evidence with regard to the benefits and risks of real-world utilisation of prasugrel as antiplatelet therapy in PCI-treated ACS patients.
No takes yet. Share an insight, caveat, or question.
Yetgin et al. (2013) conducted an observational in Acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI) (n=4,000). Prasugrel vs. Historical clopidogrel-treated patients was evaluated on Composite of all-cause mortality and nonfatal myocardial infarction. The CCR registry is a prospective observational study designed to evaluate the real-world adoption and clinical outcomes of prasugrel in 4,000 PCI-treated ACS patients.
Synapse has enriched 10 related papers. Consider them for comparative context: